Skip to main content
Figure 3 | Breast Cancer Research

Figure 3

From: Phase 2 trial of everolimus and carboplatin combination in patients with triple negative metastatic breast cancer

Figure 3

Overall survival curve in patients with triple-negative breast cancer treated with everolimus and carboplatin. Kaplan-Meier curve showing overall survival in patients with triple-negative breast cancer who were treated with everolimus and carboplatin. Median overall survival (OS) was 16 · 6 months (95% CI 7.3 months - not reached).

Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us